our scientific approach

targeting the bradykinin B2 receptor

Hereditary angioedema (HAE) most commonly occurs as a result of insufficient levels or function of a protein called C1 inhibitor (C1-INH), a naturally occurring inhibitor of the plasma kallikrein enzyme. C1-INH deficiency enables uncontrolled plasma kallikrein activity which leads to elevated levels of bradykinin resulting in swelling and pain affecting different body areas.

By inhibiting bradykinin signaling through the bradykinin B2 receptor, we have the potential to treat all clinical signs of an HAE attack and also to prevent the occurrence of attacks.

Mechanism of Action

on-demand & prophylactic treatment

HAE patients, together with their treating physicians, may opt for treatment of attacks (on-demand treatment) or may prefer to prevent attacks (prophylactic treatment) based on clinical assessment and personal choice.

Pharvaris aims to bring the promise of both of these new options to people living with HAE.

why do we believe PHVS416 & PHVS719 can work?


Deucrictibant, the chemical entity in both PHVS416 and PHVS719, is the only oral B2-receptor antagonist compound currently in clinical development. We aim to optimally formulate the compound to enable rapid onset of activity in acute treatments, and prolonged efficacy in preventive treatment.
  • Deucrictibant demonstrated highly potent and selective competitive antagonism of the B2 receptor (preclinical)
  • Deucrictibant has shown rapid and potent activity at multiple oral doses in a validated bradykinin-mediated challenge model (clinical)
  • Deucrictibant has been observed to be safe and well-tolerated at the doses studied to date (clinical)

posters and presentations